An international research team has demonstrated that a new plant-derived drug can block the progression of multiple sclerosis (MS).
University of Queensland researcher Dr Christian Gruber said the breakthrough could be a step forward in preventing and treating MS and other autoimmune diseases.
“This is a really exciting discovery because it may offer a whole new quality of life for people with this debilitating disease,” he said.
The new drug is expected to be taken by mouth, in contrast to some current MS treatments where patients need to have frequent injections.
MS is a chronic incurable condition marked by attacks that bring gradual deterioration in the patient’s health. About 23,000 people are affected in Australia and 2.5 million worldwide.
Dr Gruber said the new drug – named T20K – was extracted from a traditional medicinal plant, the Oldenlandia affinis.
The drug treatment had been successful in an animal model, and patent applications filed in several countries.
“Phase one clinical trials could begin as early as 2018,” Dr Gruber said.
“Licences have been assigned to Cyxone, a company established last year to develop this new class of drugs for the treatment of autoimmune diseases.
“Cyxone’s immediate focus is on bringing T20K through the pre-clinical program required for delivering a safe, orally active drug.”
Dr Gruber said the new treatment arose from a synthesised plant peptide, a class of drugs known as cyclotides.
“Cyclotides are present in a range of common plants, and they show significant potential for the treatment of auto immune diseases,” he said.
“The T20K peptides exhibit extraordinary stability and chemical features that are ideally what you want in an oral drug candidate.”
The international research team demonstrated in an animal model that T20K stopped progression in the normal clinical symptoms of MS.
The Latest on: Multiple sclerosis
via Google News
The Latest on: Multiple sclerosis
- NICE Gives Green Light to Multiple Sclerosis Drugon February 21, 2020 at 12:23 am
The National Institute for Health and Care Excellence (NICE) has recommended peginterferon beta-1a (Plegridy, Biogen Idec) as a treatment option for relapsing-remitting multiple sclerosis (MS) for ...
- Douglas County deputy battling multiple sclerosis sets sights on Boston Marathonon February 20, 2020 at 8:15 pm
DOUGLAS COUNTY, Colo. -- A Douglas County Sheriff's deputy is battling a debilitating disease and inspiring others through his courage. Deputy John Carrasco has multiple sclerosis. Now, he's hoping to ...
- AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of multiple sclerosison February 20, 2020 at 10:39 am
Paris, February 20, 2020, 7.30pm AB Science announces positive top-line Phase 2B/3 results for oral masitinib in progressive forms of ...
- New hope for multiple sclerosis patientson February 17, 2020 at 4:30 pm
New hope for multiple sclerosis patients Watch "Australian researchers say a drug used to treat rare disease could be used to help treat people with multiple sclerosis", a CBSN video on CBSNews.com.
- Multiple Sclerosis Treatment Market Future Opportunities, Production/Demand Analysis & Outlook To 2026on February 17, 2020 at 3:02 am
In 2020, the global Multiple Sclerosis Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2026, with a CAGR of xx% during 2020-2026. The global Multiple ...
- Multiple Sclerosis Drugs Market 2020: Industry Growth Status, Latest Developments, Revenue, Share And Demands Research Report 2025| QYR Consultingon February 13, 2020 at 1:03 am
QY Research offers its latest report on the global Multiple Sclerosis Drugs market that includes a comprehensive analysis of a range of subjects such as market growth status, competition, segmentation ...
- Consistent Efforts to Find Effective Drugs is Driving Growth of Multiple Sclerosis Drugs Market to Valuation of ~US$ 32 bn by 2027, Finds TMRon February 13, 2020 at 12:30 am
/PRNewswire/ -- Transparency Market Research has been keen following the developments happening across the global Multiple Sclerosis Drugs Market. According ...
- Selma Blair Opens Up About New Multiple Sclerosis Symptomson February 12, 2020 at 6:42 pm
Selma Blair opened up about the realities of multiple sclerosis in a revealing Instagram post. The actress detailed her uncomfortable nights dealing with muscle spasms and difficulty stretching. Selma ...
- Selma Blair Opens Up About New Multiple Sclerosis Symptoms In Revealing Instagram Poston February 12, 2020 at 2:13 pm
Selma Blair, 47, is feeling sick and opening up about her new symptoms on Instagram. The actress was diagnosed with multiple sclerosis over a year ago and has been sharing her experience with fans and ...
- Principia Biopharma: Hype Over Multiple Sclerosis "Data" Is Overblownon February 12, 2020 at 8:05 am
We are short shares of Principia Biopharma (PRNB). Last week, Sanofi, the large pharma company that has licensed Principia’s BTK inhibitor SAR442168 for use in multiple sclerosis, announced that the ...
via Bing News